Table 1.
Clinicopathological characteristics of soft tissue sarcoma patients.
| Variable | All Patients (n = 87) | Standard Treatment a (n = 74) | Preoperative Adjuvant Treatment b (n = 13) | p Value c Between a and b | |
|---|---|---|---|---|---|
| Subgroup | No. (%) | No. (%) | No. (%) | ||
| Age (years) | Mean (range) | 52.5 (12–91) | 52.3 (19–91) | 53.6 (12–83) | 0.839 |
| <40 | 23 (26.4) | 20 (27.0) | 3 (23.1) | 0.533 | |
| >40 | 64 (73.6) | 54 (73.0) | 10 (76.9) | ||
| Gender | female | 43 (49.4) | 37 (50.0) | 6 (46.2) | 0.518 |
| male | 44 (50.6) | 37 (50.0) | 7 (53.8) | ||
| Histiotype d | MFH/PMS | 24 (27.6) | 20 (27.0) | 4 (30.8) | 0.273 |
| LPS | 22 (25.3) | 22 (29.7) | 0 (0.0) | ||
| LMS | 16 (18.4) | 12 (16.2) | 4 (30.8) | ||
| SS | 6 (6.9) | 5 (6.8) | 1 (7.7) | ||
| MPNST | 4 (4.6) | 3 (4.1) | 1 (7.7) | ||
| AS | 4 (4.6) | 4 (5.4) | 0 | ||
| others | 11 (12.6) | 8 (10.8) | 3 (23.1) | ||
| Stage | I | 14 (16.1) | 14 (18.9) | 0 (0.0) | 0.377 |
| II | 35 (40.2) | 29 (39.2) | 6 (46.1) | ||
| III | 25 (28.7) | 20 (27.0) | 5 (38.5) | ||
| IV | 13 (14.9) | 11 (14.9) | 2 (15.4) | ||
| Grade | Low | 26 (29.9) | 23 (31.1) | 3 (23.1) | 0.319 |
| Intermediate | 8 (9.2) | 8 (10.8) | 0 (0.0) | ||
| High | 53 (60.9) | 43 (58.1) | 10 (76.9) | ||
| Site | Extremity | 40 (46.1) | 32 (43.2) | 8 (61.5) | 0.034 |
| Trunk | 14 (16.1) | 12 (16.2) | 2 (15.4) | ||
| Head and neck | 7 (8.0) | 7 (9.5) | 0 (0.0) | ||
| Abdomen and pelvis | 23 (26.4) | 22 (29.7) | 1 (7.7) | ||
| Thorax | 3 (3.4) | 1 (1.4) | 2 (15.4) | ||
| Size (cm) | <5 | 27 (31.0) | 25 (33.8) | 2 (15.4) | 0.035 |
| >5 to <10 | 27 (31.0) | 19 (25.6) | 8 (61.5) | ||
| >10 | 33 (37.9) | 30 (40.5) | 3 (23.1) | ||
| Depth | Superficial | 19 (21.8) | 18 (24.3) | 1 (7.7) | 0.166 |
| deep | 68 (78.2) | 56 (75.7) | 12 (92.3) | ||
| Margin (mm) | >10 | 5 (5.7) | 4 (5.4) | 1 (7.5) | 0.995 |
| 1–10 | 20 (23.0) | 17 (23.0) | 3 (23.1) | ||
| <1 | 12 (13.8) | 10 (13.5) | 2 (16.7) | ||
| Involved | 44 (50.6) | 38 (51.3) | 6 (46.2) | ||
| Unknown | 6 (6.9) | 5 (6.8) | 1 (7.5) | ||
| Local Recurrence | Yes | 9 (89.7) | 8 (10.8) | 1 (7.7) | 0.597 |
| No | 78 (10.3) | 66 (89.2) | 12 (92.3) | ||
| Overall Survival (months) | Median (95% CI) | 55 (42–68) | 56 (45–67) | 40 (19–61) | 0.744 |
a Standard treatment includes wide section only for small and/or subcutaneous tumours and surgery plus postoperative radiotherapy for high risk deep tumours; b Doxorubicin (one dose as radiosensitizer) followed by radiotherapy (28); c Statistical methods were t test, Chi-squared test, Fisher test or log rank test; d Histiotype indicates subtypes of soft tissue sarcomas based on histological characteristics, including MFH/PMS: malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma; LPS: liposarcoma; LMS: leiomyosarcoma; SS: synovial sarcoma; MPNST: malignant peripheral nerve sheath tumour; AS: angiosarcoma; and others.